Comparison of the clinical characteristics of CD5+vs. CD5− DLBCL patients in the training set showed that CD5+ DLBCL patients were more frequently elderly (>60 years), and had B-symptoms, high performance status, an IPI score >2, and BM involvement (Table 1). The gene discussed is CD5; the disease is diffuse large B-cell lymphoma.